CSI Market
Sign In | Register

Calithera Biosciences Inc (CALA) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CALA Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Calithera Biosciences Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2022)
12 Months 		(Sep 30 2022) (Jun 30 2022) (Mar 31 2022) (Dec 31 2021)
Operating Activities
Income-39.65
Depreciation & amortization0.26
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation4.03
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants-2.42
Investment Income Amortization Of Premium-
Increase Decrease In Contract With Customer Liability-
Investment Income Net Amortization Of Discount And Premium-
Gain Loss On Remeasurement Of Lease Liability-
Transaction Costs Allocable To Warrant Liabilities0.48
Non Cash Lease Expense0.84
Increase Decrease In Lease Liability-1.02
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable-2.92
Increase (Decrease) in Accrued Liabilities-3.88
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets0.74
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-43.61
Investing Activities
Capital Expenditures-0.13
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Available-for-sale Securities0.00
Payments to Acquire Available-for-sale Securities0.00
Real Estate Investments0.00
Increase (Decrease) in Restricted Cash0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-0.13
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.15
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock Under Stock Purchase Agreement Net-
Proceeds From Issuance Secondary Offering-
Proceeds From Issuance Of Common Stock And Warrants From Public Offering Net8.50
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities9.66
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-43.74
Total Cash Flow-34.09
4 historic quarters locked

Sign in to unlock the full Calithera Biosciences Inc cash flow history.

Sign In Create Free Account

About Calithera Biosciences Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0000950170-23-011047

Figures are derived from filed reports and may be restated. Historical data is subject to revision.